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AL amyloidosis is caused by clonal plasma cells that produce immunoglobulin light chains which misfold and get deposited as
amyloidﬁbrils.Therapydirectedagainsttheplasmacellcloneleadstoclinicalbeneﬁt.Melphalanandcorticosteroidshavebeenthe
mainstay of treatment for a number of years and the recent availability of other eﬀective agents (IMiDs and proteasome inhibitors)
has increased treatment options. Autologous stem cell transplant (ASCT) has been used in the treatment of AL amyloidosis for
many years. It is associated with high rates of hematologic response and improvement in organ function. However, transplant
carriesconsiderablerisks.Carefulpatientselectionisimportanttominimizetransplantrelatedmorbidityandmortalityandensure
optimalpatientoutcomes.AsnewermoreaﬀectivetherapiesbecomeavailabletheroleandtimingofASCTintheoveralltreatment
strategy of AL amyloidosis will need to be continually reassessed.
1.Introduction
Amyloidosis is a disease of protein misfolding in which the
involved protein acquires an abnormal beta-pleated sheet
conﬁguration rather than the native alpha helical state [1].
The amyloid protein is insoluble, and its deposition in
various tissues causes tissue damage and organ dysfunction.
Amyloidosis can be of various types based on the precursor
protein involved in amyloid formation. More than 20 diﬀer-
enthumanﬁbrillaramyloidproteinshavebeendescribed[2],
and accurate identiﬁcation of the type is crucial to treatment
planning. It is also important to distinguish localized from
systemic amyloidosis since patients presenting with localized
amyloidosis generally do not need systemic treatment.
The most common type of systemic amyloidosis (primary
amyloidosis or AL amyloidosis) is caused by production
of immunoglobulin light chain or light chain fragment
secondary to an underlying plasma cell dyscrasia. Other
systemic amyloidoses (secondary amyloidoses) include AA
amyloid(causedasaresultofchronicinﬂammatorydisease),
ATTR caused by alteration in transthyretin (TTR) protein
because of one of several mutations (familial amyloid)
or misfolding of wild-type transthyretin protein (senile
amyloidosis), and dialysis-related amyloidosis (deposition of
beta 2 microglobulin).
Primary amyloidosis is the only type of systemic amy-
loidosis that responds to cytotoxic chemotherapy directed
against the abnormal plasma cell clone, the source of
amyloidogenic light chains. Other treatment strategies to
prevent amyloid formation by altering the equilibrium
between soluble precursor and insoluble ﬁbrils, destabilizing
the amyloid ﬁbril protein, or antibodies directed against
amyloid ﬁbrils are being investigated and show promise but
are not available for clinical use [3–5].
This paper will focus on the role of autologous hemato-
poietic stem cell transplantation for primary systemic amy-
loidosis.
2. Treatment of Amyloidosis
The ultimate goal of treatment of amyloidosis is to improve
organ function, prolong survival, and enhance quality of
life. The mainstay of treatment is cytotoxic chemotherapy
directed against the plasma cells to decrease the level of
circulating amyloid causing light chains. This, in turn, can
be expected to slow down further amyloid deposition and
improve the prospects for mobilization or dissolution of
already deposited amyloid and reversal of organ damage.
Treatment of AL amyloid has evolved over the years and
has closely paralleled the developments in multiple myeloma2 Bone Marrow Research
therapy since the fundamental underlying problem in both
these conditions is the same. Early studies established
melphalan as an eﬀective agent. In randomized controlled
trials comparing melphalan plus prednisone to colchicine in
patients with AL amyloidosis, the melphalan and prednisone
combination was associated with objective responses and
prolonged survival compared to colchicine [6, 7]. Melphalan
h a sc o n t i n u e dt ob eak e ya g e n ti nt h et r e a t m e n to f
amyloidosis. Melphalan combined with dexamethasone is
considered a “standard” ﬁrst line therapy. Palladini et al.
showed that this combination results in high response
rates, 67% hematologic response including 33% complete
response, and 48% of patients had objective organ function
response. Responses were durable, and CR was maintained
in 9 of 15 patients after a median of 4.8 years. Six-
year progression-free survival was 40%, and median overall
survival was 5.1 years [8, 9]. Other studies with oral
or intravenous melphalan combined with dexamethasone
have shown less robust responses with complete response
rates of 11 and 13%, likely because of diﬀerent patient
characteristics especially cardiac involvement [10, 11]. The
development of free immunoglobulin light chain (FLC)
assay allowed quantitation of circulating amyloidogenic light
chains. Reduction in FLC with treatment was subsequently
showntobeassociatedwithdecreaseinamyloidload,clinical
improvement, and survival beneﬁt [12]. The introduction
of new agents (IMiDs and bortezomib) in the last 10
years has revolutionized the treatment of multiple myeloma
and improved survival [13]. Since the underlying problem
in amyloidosis is also plasma cell dyscrasia, it is logical
to expect that these agents will also be eﬀective in the
treatment of primary amyloidosis. Studies with thalidomide,
lenalidomide, and bortezomib indeed demonstrate activity
of these agents. Bortezomib appears to be highly eﬀective
with hematologic response rates of 50%– 94% and CR rates
of 20–44% in diﬀerent studies [14–16].
3.Autologous StemCellTransplant(ASCT)
High-dose chemotherapy followed by ASCT reliably pro-
duces hematologic complete remissions in a sizable pro-
portion of patients with multiple myeloma. Because plasma
cell dyscrasia is the underlying cause of AL amyloidosis,
ASCT has also been adopted for the treatment of AL
amyloidosis. Early studies of ASCT reported signiﬁcant
toxicity including mortality rate of over 40% in one small
study [17]. Subsequent studies showed better results and
showed that with careful patient selection transplant can be
performedwithacceptabletoxicity[18,19].Autologousstem
cell transplant has remained an important treatment option
for systemic AL amyloidosis.
3.1. Selection of Patients. Although mortality from autolo-
gous stem cell transplant has continued to decrease over
time, [20, 21] the procedure remains high risk, and careful
selectionofpatientsiscriticalforgoodoutcomes.Bestresults
were obtained in patients with nephrotic syndrome as the
predominant manifestation of amyloidosis. Patients with
multiple organ involvement, particularly those with cardiac
dysfunction, fare poorly with high risk of morbidity and
mortality [22]. Many patients with primary amyloidosis are
too sick to undergo autologous stem cell transplant.
Predictorsofpoorprognosisinpatientswithamyloidosis
include the number of organs involved, cardiac involvement
evidenced by clinical cardiac dysfunction or elevation of
cardiac biomarkers (troponin-T and N-terminal brain natri-
uretic peptide (NT-pro-BNP)), pretransplant free light chain
ratio, and elevated serum uric acid [23–26]. The number of
organs involved and the extent of cardiac dysfunction are by
far the dominant predictors of prognosis with or without
transplant [22, 26]. Excessive ﬂuid retention during stem
cell mobilization and harvest may be a reﬂection of limited
cardiac and/or renal reserve and is associated with poor
outcomesduringtransplant[27].Althougholderindividuals
are more likely to have comorbidities, age per se is not
a contraindication, and older individuals can successfully
undergo autologous HSCT [28]. A risk-adapted approach
to transplant has been suggested wherein the melphalan
dose in the conditioning regimen is lowered for individuals
considered at high risk for transplant toxicity. However,
the risk-adjusted lowering of conditioning chemotherapy is
associated with reduced response rates [29]. The risks and
beneﬁts of transplant have to be carefully evaluated for each
individualpatienttoensureoptimalbalancebetweeneﬃcacy
and toxicity.
3.2. Outcomes. Autologous stem cell transplant is associated
with substantial likelihood of hematologic response includ-
ing organ function improvement. Long-term posttransplant
follow-up studies show the durability of responses and better
survival of responders. Cibeira et al. reported longterm
outcomes of 421 AL patients transplanted between 1994 and
2008. Hematologic CR rate was 43%, and 78% of complete
responders had improvement in organ function. For patients
achieving a CR the median event free survival (EFS) and
overall survival (OS) were 8.3 and 13.2 years compared to
organ response rate of 52%, EFS of 2 years, and OS of 5.9
years in those who did not achieve hematologic CR [20].
Investigators from Mayo Clinic reported their experience
with 434 transplants since 1996. Hematologic response rate
of 76% (CR rate 38.7%) and organ response rate of 46.8%
were described. Median OS was not reached for patients
achieving hematologic CR and was 107 months and 32
months, respectively, for those with partial response and
no response [30]. Outcomes of 107 recipients of ASCT
performed at 48 centers between 1995 and 2001 were
reported by Center for International Blood & Marrow
Transplant Research (CIBMTR) investigators. A relatively
high transplant-related mortality of 18% at 30 days was
noted. One-year and 3-year survival rates were 66% and
5 6 % ,r e s p e c t i v e l y .T h eo u t c o m e sw e r eb e t t e ri np a t i e n t s
transplanted in later years possibly related to better patient
selection, improved supportive care and/or physician expe-
rience [31]. These and other studies show that hematologic
response, particularly CR is associated with better survival
and improvement in organ function, including renal andBone Marrow Research 3
cardiac functions in substantial proportion of patients [32–
34]. Histologic regression of amyloid has been shown but
seems to occur only in patients who achieve normalization
of free light chains [35].
4.Hematopoietic StemCellTransplantversus
Other Therapies
The exact role of autologous stem cell transplant in the
treatment of primary AL amyloidosis and the beneﬁt relative
to other available therapies continues to be debated. It has
been argued that apparent superior outcomes of patients
undergoing transplant are a function of selection bias since
only healthier patients, who are destined to do better,
are selected to undergo transplant. A retrospective study
looked at outcomes of patients who were transplant eligible
but did not undergo transplant. Transplant eligibility itself
identiﬁed a good risk group who did better than transplant
ineligible patients even with nontransplant therapy [36]. A
c a s ec o n t r o ls t u d yc o m p a r e dt h eo v e r a l ls u r v i v a lo f6 3A S C T
recipients with matched controls not undergoing transplant.
The groups were matched for age, gender, time to pre-
sentation, left ventricular function, serum creatinine, inter-
ventricular septal thickness, nerve involvement, and 24-hour
proteinuria). One-, 2-, and 4-year overall survival rates for
thetransplantversusnon-transplantgroupswere89%versus
71%, 81% versus 55%, and 77% versus 41%, respectively
[37] .T h e s ed a t as h o w i n gb e t t e ro v e r a l ls u r v i v a la sw e l la s
studies demonstrating improved quality of life [38]p r o v i d e
strong arguments in support of the role of autologous HSCT
for AL amyloidosis. However, randomized trials have not
substantiated the beneﬁt of autologous transplant. In a
randomized control trial 100 patients with AL amyloidosis
aged 18–70 years were randomized between HSCT and
conventional therapy. The overall survival was similar in
the two arms [39]. High transplant-related mortality of
24% in this study is a notable concern. The publication
generated many letters to the journal highlighting concerns
about patient selection, inclusion of high-risk patients which
necessitated reduction in melphalan dose in 10 of 37
patients, lack of information about cardiac biomarkers, and
whether transplants performed at low volume centers in
this multicenter study may have biased the results against
ASCT [40–42]. A systematic review and meta-analysis of 1
randomizedcontroltrial,2othercontrolstudies,and9single
arm studies also did not provide a conclusive answer. The
study did not ﬁnd a survival beneﬁt with transplant but the
authors commented that the quality of evidence was low,
indicating a need for well-designed and adequately powered
trials to better address the role of AHCT in AL amyloidosis
[43].
Therapeutic options for AL amyloidosis are constantly
c h a n g i n g .A sn e w e r ,m o r ee ﬀective therapies become avail-
able, and the role of transplant will need to be reevaluated.
Modern, bortezomib-based therapies are associated with
response rates approaching those obtained by transplant.
Bortezomib as monotherapy or with other agents is active in
AL amyloidosis, and produces rapid responses and high rates
of hematologic and organ response [44–46]. The durability
of these responses is unclear at present since only relatively
short followup is available. A phase III, multicenter study
evaluating melphalan and dexamethasone with or without
bortezomib in patients with previously untreated systemic
AL amyloidosis is currently ongoing (NCT01078454). Borte-
zomib has also been used for amyloidosis relapsing after
transplant. It is eﬀective in that setting and can lead to
normalization of free light chains and potentially render
patients previously not candidates for transplant safe to
undergo high-dose therapy [47].
The availability of multiple very active treatment options
for patients is clearly welcome news for patients with this
devastating disorder. Conventional therapy with bortezomib
or other agents and ASCT should not be seen as competitive
but rather additive or complementary in nature. Achieving
aC Ri sak e yp r e d i c t o ro fo v e r a l ls u r v i v a l .A S C Ta f t e ra
bortezomib-based induction regimen may improve the pro-
portion of patients achieving complete remission. However,
that remains to be shown in clinical trials. Amyloidosis is a
heterogeneous disease with a large variation in the range and
severity of clinical presentations, tempo of disease progres-
sion,andcomorbidities.Thechallengeforthephysiciansisto
individualizetreatmentbyselectingtheoptimalcombination
or sequence of the various therapies to achieve best possible
results for the patient. Clearly, optimal approach will be
diﬀerent for each patient depending on their disease status
(number of organs involved, organ function), overall health
status and co-morbidities, and their personal choice and
goals.
5. Conclusions
ASCT is an eﬀective therapy for primary amyloidosis. It is
associatedwithconsistentlyhighhematologic responserates,
which lead to improvement in organ function, quality of life,
and survival. Best results are obtained in patients with 1-
2 organ involvement and no cardiac dysfunction. Patients
with multiple (more than 2) organ involvement, particularly
advancedcardiacinvolvementandrenalinsuﬃciency,arenot
suitable candidates for this therapy. The question whether
ASCT should be the preferred therapy for patients who
are healthy enough to tolerate it has not been answered
deﬁnitely. In the consensus opinion of physicians at the
Mayo Clinic experienced in the treatment of amyloidosis the
answertothisquestionis yes[48].Theimportanceofpatient
selection to ensure safety and optimal outcomes cannot be
overemphasized. The role of HSCT in the overall treatment
of AL amyloidosis is likely to evolve as new, more eﬀective
therapies become available and will need to be continually
assessed in future prospective trials.
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